Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

被引：10
|
作者：
Ettl, Johannes [1 ]
机构：
[1] Tech Univ Munich, Dept Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany
来源：
BREAST CARE | 2016年 / 11卷 / 03期
关键词：
Advanced breast cancer; Palbociclib; CDK4/6; Endocrine therapy; Cell cycle; DEPENDENT KINASE 4/6; 1ST-LINE TREATMENT; SUBGROUP ANALYSIS; LETROZOLE L; PD; 0332991; PALOMA-1/TRIO-18; COMBINATION; TRIAL; EFFICACY; SAFETY;
D O I：
10.1159/000447417
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed. (C) 2016 S. Karger GmbH, Freiburg
引用
收藏
页码：174 / 176
页数：3
相关论文
共 50 条
  • [21] Clarithromycin Interactions with Palbociclib (CDK4/6 Inhibitor)
    Hu, Xiuqiong
    Yang, Wei
    Liu, Lanjie
    Qin, Hua
    LATIN AMERICAN JOURNAL OF PHARMACY, 2021, 40 (07): : 1698 - 1707
  • [22] Ribociclib for HR-Positive, Advanced Breast Cancer
    Araki, Kazuhiro
    Miyoshi, Yasuo
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 288 - 288
  • [23] CDK4/6-Inhibition in HR+, HER2-advanced breast cancer: First Real-World Data substantiate Efficacy and Tolerability of Palbociclib even in clinical Practice
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (05) : 246 - 246
  • [24] Everolimus in HR-Positive Advanced Breast Cancer
    Tartarone, Alfredo
    Lerose, Rosa
    Aieta, Michele
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (18): : 1739 - 1739
  • [25] Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
    Palumbo, Alison
    Lau, Gary
    Saraceni, Megan
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 178 - 185
  • [26] Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
    Rossi, Lorenzo
    McCartney, Amelia
    Risi, Emanuela
    Malorni, Luca
    Biganzoli, Laura
    Di Leo, Angelo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [27] PALBOCICLIB Cyclin CDK4/CDK6 Inhibitor Oncolytic
    Haddley, K.
    DRUGS OF THE FUTURE, 2013, 38 (11) : 745 - 755
  • [28] Pfizer's CDK4/6 inhibitor approved for advanced breast cancer
    Morrison, Chris
    NATURE BIOTECHNOLOGY, 2015, 33 (04) : 323 - 324
  • [29] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [30] Pfizer's CDK4/6 inhibitor approved for advanced breast cancer
    Chris Morrison
    Nature Biotechnology, 2015, 33 : 323 - 324
12345